Horizon Pharma plc Announces Settlement of PENNSAID(R)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Amneal Pharmaceuticals LLC

DUBLIN, IRELAND--(Marketwired - Apr 25, 2016) - Horizon Pharma plc ( NASDAQ : HZNP ), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliates have entered into a settlement and license agreement with Amneal Pharmaceuticals LLC to resolve pending patent litigation involving PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID® 2%).

Under the settlement and license agreement, Horizon has granted Amneal the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the United States under Amneal's Abbreviated New Drug Application (ANDA), beginning January 10, 2029 or earlier under certain circumstances.

The agreement includes a stipulation by the parties requesting dismissal without prejudice of the lawsuit filed by Horizon in the U.S. District Court for the District of New Jersey relating to the ANDA filed by Amneal with the U.S. Food and Drug Administration for a generic version of PENNSAID 2%.

Details of the settlement are confidential and the agreement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.

About PENNSAID® 2% PENNSAID (diclofenac sodium topical solution) 2% w/w is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain of osteoarthritis (OA) of the knee(s). PENNSAID 2% contains diclofenac sodium, an NSAID, and also includes dimethyl sulfoxide (DMSO), a powerful penetrating agent that helps ensure that diclofenac sodium is absorbed through the skin to the site of inflammation and pain. PENNSAID 2% is an alternative to oral NSAID treatment, reducing systemic exposure to a fraction of that provided by the oral NSAID diclofenac. The only topical NSAID offered with the convenience of a metered-dose pump, PENNSAID 2% is applied in two pumps, twice daily, to the site of OA knee pain. For more information, please see www.PENNSAID.com.

IMPORTANT SAFETY INFORMATION

WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK

Heart Risk

  • Non-steroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious heart clotting events, heart attack and stroke, which can kill you. This risk may increase with longer use. Patients with heart disease or risk factors for heart disease may be at greater risk.
  • PENNSAID 2% should not be used if you are in the hospital for certain heart surgeries.

Stomach and Intestine Risk

  • NSAIDs cause an increased risk of serious stomach and intestine events including bleeding, ulcers and holes in the stomach or intestines, which can kill you. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious stomach and intestine events.

CONTRAINDICATIONS

  • DO NOT USE PENNSAID 2% if you:
    • are in the hospital for certain heart surgeries.
    • know you are allergic to diclofenac sodium or any other ingredient of PENNSAID 2%.
    • have experienced asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, allergic reactions that will rarely kill you, to NSAIDs have been reported in such patients.

WARNINGS AND PRECAUTIONS

  • To minimize the potential for increased risk of serious heart events while being treated with an NSAID, use the lowest effective dose for the shortest duration possible.
  • Elevation of one or more liver tests may occur during therapy with NSAIDs. PENNSAID 2% should be discontinued immediately if abnormal liver tests persist or worsen.
  • Use with caution in patients with fluid retention or heart failure.
  • Hypertension can occur with NSAID treatment. Monitor blood pressure closely with PENNSAID 2% treatment.
  • Long-term use of NSAIDs can result in severe kidney injury. Use PENNSAID 2% with caution in patients at greatest risk of this reaction, including the elderly, those with impaired kidney function, heart failure, liver dysfunction and those taking diuretics and ACE-inhibitors (certain blood pressure medicines).
  • Severe allergic reactions may occur without prior use of PENNSAID 2%. NSAIDs can cause serious skin reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), which can kill you.
  • Wash and dry hands before and after use. Avoid contact of PENNSAID 2% with the eyes, nose and mouth.
  • PENNSAID 2% was not studied under the conditions of heat application, complete covering bandages or exercise; therefore, concurrent use of PENNSAID under these conditions is not recommended.
  • Do not:
    • Apply PENNSAID 2% to open wounds.
    • Shower for at least 30 minutes after applying PENNSAID 2%. 
    • Wear clothing over the PENNSAID 2% treated knee until the treated knee is dry.
  • Protect treated knee(s) from natural or artificial sunlight.
  • Protect treated knee(s) from sunlight (real and tanning booths).
  • Topicals, such as sunscreen and bug repellent, should not be used until after PENNSAID 2% treated knee(s) are completely dry.
  • Do not use with oral NSAIDs unless your doctor says it is OK and you have lab tests to check your progress.
  • There is no consistent evidence that regular use of aspirin lessens the increased risk of serious heart events, such as heart clotting, heart attack and stroke associated with NSAID use. As with all NSAIDs, regular administration of PENNSAID 2% and aspirin is not generally recommended because of the potential of increased risks.

ADVERSE REACTIONS

  • The most common adverse events in a phase 2 clinical trial of PENNSAID 2% were application site reactions, such as dryness (22%), peeling (7%), redness (4%), itching (2%), pain (2%), skin hardening (2%), rash (2%) and scabbing ( < 1%). Other adverse reactions occurring in > 1% of patients receiving PENNSAID 2% included bladder infection (3%), bruising (2%), sinus congestion (2%) and nausea (2%).

USE IN SPECIFIC POPULATIONS

  • PENNSAID 2% should not be used in pregnant woman or in women who are breastfeeding and is not approved for use in children. 

For more information on PENNSAID 2%, please see the Medication Guide and Full Prescribing Information , available at www.PENNSAID.com .

About Horizon Pharma plc   Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, rheumatology and primary care business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com . Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the anticipated results of or future actions of the parties under the settlement and license agreement for PENNSAID 2%. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, risks regarding whether the U.S. Federal Trade Commission or Department of Justice will challenge the enforceability of or seek to enjoin the entry into the settlement and license agreement, whether the U.S. District Court will grant an order dismissing the litigation, whether additional third parties may seek to market generic versions of PENNSAID 2% by filing ANDAs with the FDA and the results of any litigation that Horizon files to defend or assert its patents against such third parties, the occurrence of events under the settlement and license agreement that would allow Amneal to market its generic version of PENNSAID 2% earlier than anticipated, and other risk factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations Investor-relations@horizonpharma.com Tina Ventura Vice President, Investor Relations Investor-relations@horizonpharma.com U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications gcurtis@horizonpharma.com Ireland Media: Ray Gordon Gordon MRM ray@gordonmrm.ie

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 21

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 86

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 81

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 37

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 165

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 24

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 145

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 207

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading

Top 5 Most Recently Viewed Articles

AXIA Time Honors Ohio State's Title with Unique Watch Sets

Updated Category News Views 254

Introducing AXIA Time's Exclusive Collection AXIA Time, the official timepiece of prominent college football events, is excited to unveil a special collaboration with Ryan Day. This partnership marks a notable celebration for Ohio State University's recent achievements, delivering unique limited-edition items that honor the history of its football program. Limited Edition...

Continue Reading
AstraZeneca's Historic NYSE Move Signals Market Shift

Updated Category News Views 53

AstraZeneca's Gigantic Leap In the hustle of Wall Street's whirring machine, June 5, 2026, dawned with a palpable buzz. Why? AstraZeneca (NYSE:AZN) just pulled off the biggest market cap transfer in the New York Stock Exchange's epic 234-year saga. Now that's a splash, not just a ripple. It’s like watching a giant whale breach in an already crowded ocean. But what does...

Continue Reading
Dr. Gunther von Hagens: A Legacy of Human Anatomy

Updated Category News Views 112

A Groundbreaking Visionary in Anatomy Passes The world has lost a pioneer in anatomical science. Dr. Gunther von Hagens, inventor of the groundbreaking technique known as Plastination and creator of the BODY WORLDS exhibitions, passed away on July 24, 2026, at the age of 81. His innovative work fundamentally changed the way we view and understand human anatomy. Not quite...

Continue Reading
Exploring the Future of Yachting: Insights from Monaco's Symposium

Updated Category News Views 138

Reviving Ambitions at the Yacht Club de Monaco The Yacht Club de Monaco recently held a significant event, the 17th Business Symposium – La Belle Classe Superyachts, in collaboration with UBS. This prestigious dinner debate has evolved into more than just a gathering; it has transformed into a critical platform where influential figures in the yachting industry share...

Continue Reading
Marex Group Plc Set to Release Q3 2024 Earnings Soon

Updated Category News Views 51

Marex Group Plc Set to Release Q3 2024 Earnings Soon Marex Group plc (NASDAQ: MRX) has officially announced that it will be unveiling its third quarter results for the fiscal year 2024. This significant event is scheduled to take place before the market opens on an upcoming Thursday in November. Investors and analysts are eagerly anticipating this release, which will...

Continue Reading